LSV Asset Management
PCRX icon

LSV Asset Management’s Pacira BioSciences PCRX Stock Holding History

LSV Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
608,376
+91,276
+18% +$2.16M 0.03% 373
2026
Q1 		$11.7M Buy
517,100
+197,300
+62% +$4.38M 0.03% 380
2025
Q4 		$8.28M Buy
319,800
+205,500
+180% +$4.89M 0.02% 420
2025
Q3 		$2.95M Buy
114,300
+19,100
+20% +$469K 0.01% 533
2025
Q2 		$2.27M Buy
95,200
+13,100
+16% +$330K 0.01% 539
2025
Q1 		$2.04M Buy
82,100
+64,800
+375% +$1.55M ﹤0.01% 562
2024
Q4 		$326K Sell
17,300
-12,600
-42% -$221K ﹤0.01% 717
2024
Q3 		$450K Buy
29,900
+13,767
+85% +$235K ﹤0.01% 712
2024
Q2 		$462K Buy
+16,133
New +$459K ﹤0.01% 735

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management's PCRX Position: Q2 2026 in Review

LSV Asset Management increased its Pacira BioSciences (PCRX) stake by 18% in Q2 2026, buying an estimated $2.16M and bringing the position to 608,376 shares worth $15.4M. The position accounts for 0.03% of the portfolio, ranked #373.

LSV Asset Management first reported a position in PCRX in Q2 2024 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • LSV Asset Management held 608,376 shares of Pacira BioSciences worth $15.4M as of Q2 2026.
  • LSV Asset Management bought 91,276 Pacira BioSciences shares in Q2 2026, an estimated $2.16M.
  • Pacira BioSciences made up 0.03% of LSV Asset Management's portfolio in Q2 2026, its #373 holding.
  • LSV Asset Management first reported a position in Pacira BioSciences in Q2 2024 and has held it in 9 quarters since.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.